Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention - FDA Guidance Document | Global Key Solutions

Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention

Detailed guidance document from FDA and regulatory agencies.

Document Details

Document Type

Guidance Document

Issue Date

October 27, 2022

Last Updated

October 31, 2022

Office

Center for Drug Evaluation and Research

Document ID

b0e5f4fd-4c99-48d2-ad08-77dfb3fc2cc2

Related Documents

Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment Guidance for Industry

Guidance DocumentNovember 1, 2019Center for Drug Evaluation and Research

View Details →

Pulmonary Tuberculosis: Developing Drugs for Treatment

Guidance DocumentDecember 14, 2022Center for Drug Evaluation and Research

View Details →

Postoperative Nausea and Vomiting: Developing Drugs for Prevention

Guidance DocumentOctober 17, 2024Center for Drug Evaluation and Research

View Details →

Quick Actions

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox